These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 15755796

  • 21. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
    Moride Y, Ducruet T, Boivin JF, Lavoie F, Rochon S.
    Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
    [Abstract] [Full Text] [Related]

  • 22. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK, Castellsague J, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ, Wentworth C, Burke TA, Makuch RW.
    Pharmacoepidemiol Drug Saf; 2004 May 24; 13(5):277-87. PubMed ID: 15133778
    [Abstract] [Full Text] [Related]

  • 27. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E, Toubouti Y, Hunsche E.
    Rheumatology (Oxford); 2006 Jul 24; 45(7):903-10. PubMed ID: 16461440
    [Abstract] [Full Text] [Related]

  • 28. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
    Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A.
    Arch Intern Med; 2005 Jan 24; 165(2):189-92. PubMed ID: 15668365
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.
    Pharmacoepidemiol Drug Saf; 2005 Jul 24; 14(7):437-41. PubMed ID: 15937867
    [Abstract] [Full Text] [Related]

  • 31. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C, Stafford RS, Alexander GC.
    Arch Intern Med; 2005 Jan 24; 165(2):171-7. PubMed ID: 15668363
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J, Diggins DA, Morrill GB.
    Ann Pharmacother; 2005 May 24; 39(5):797-802. PubMed ID: 15797981
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
    Moride Y, Ducruet T, Rochon S, Lavoie F.
    Rheumatology (Oxford); 2003 Nov 24; 42 Suppl 3():iii17-22. PubMed ID: 14585914
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 24; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 40. Adoption of celecoxib and rofecoxib: a nationwide database study.
    Helin-Salmivaara A, Huupponen R, Virtanen A, Klaukka T.
    J Clin Pharm Ther; 2005 Apr 24; 30(2):145-52. PubMed ID: 15811167
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.